EnteroBiotix Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
48
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$25.1M
- Investors
-
20
EnteroBiotix General Information
Description
Developer of microbiome-modulating drugs designed to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics for patients with serious unmet medical needs and addresses them through a pipeline of tailored, high-diversity products that fortify and restore the microbiome, enabling physicians to prevent and treat debilitating infections and diseases.
Contact Information
Website
www.enterobiotix.comCorporate Office
- Phoenix House, Phoenix Crescent
- Strathclyde Business Park, Lanarkshire
- Bellshill ML4 3NJ
- Scotland, United Kingdom
Corporate Office
- Phoenix House, Phoenix Crescent
- Strathclyde Business Park, Lanarkshire
- Bellshill ML4 3NJ
- Scotland, United Kingdom
EnteroBiotix Timeline
EnteroBiotix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC (Series A) | 30-Apr-2026 | $25.1M | Completed | Clinical Trials - Phase 2 | ||
| 10. Later Stage VC | 26-Mar-2024 | Completed | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC | 14-Sep-2022 | Completed | Clinical Trials - Phase 2 | |||
| 8. Early Stage VC (Series A) | 07-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 7. Secondary Transaction - Private | 03-Aug-2021 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 01-Nov-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Seed Round | 29-May-2019 | Completed | Clinical Trials - Phase 2 | |||
| 4. Seed Round | Completed | Startup | ||||
| 3. Seed Round | 31-May-2017 | $620K | $620K | Completed | Startup | |
| 2. Accelerator/Incubator | Completed | Startup |
EnteroBiotix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 227,107 | $0.001343 | $2.16 | $2.16 | 1x | $2.16 | 2.44% | |
| Ordinary | 10,000 | $0.001343 | $2.01 | $2.01 | 1x | $2.01 | 0.11% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
EnteroBiotix Comparisons
Industry
Financing
Details
EnteroBiotix Competitors (33)
One of EnteroBiotix’s 33 competitors is NovaBiotics, a Venture Capital-Backed company based in Aberdeen, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom | ||||
| Quorum Innovations | Formerly VC-backed | Sarasota, FL | ||||
| Eligo Bioscience | Venture Capital-Backed | Paris, France | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| 4D pharma | Corporation | Leeds, United Kingdom |
EnteroBiotix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EnteroBiotix Patents
EnteroBiotix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202418792-D0 | Microbial formulation | Pending | 20-Dec-2024 | ||
| GB-202104668-D0 | Covid-19 control | Inactive | 31-Mar-2021 | ||
| GB-202104666-D0 | Covid-19 treatment | Inactive | 31-Mar-2021 | ||
| GB-202004993-D0 | Covid-19 control | Inactive | 03-Apr-2020 | ||
| GB-202004655-D0 | Covid-19 treatment | Inactive | 30-Mar-2020 |
EnteroBiotix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EnteroBiotix Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kineticos Life Sciences | Other | Minority | ||
| Home Furnishings Direct | Corporation | Minority | ||
| Pioneer Group | Venture Capital | Minority | ||
| The Scottish National Investment Bank | Investment Bank | Minority | ||
| Yike Zhengrun Investment Group | Venture Capital | Minority |
EnteroBiotix FAQs
-
When was EnteroBiotix founded?
EnteroBiotix was founded in 2017.
-
Where is EnteroBiotix headquartered?
EnteroBiotix is headquartered in Bellshill, United Kingdom.
-
What is the size of EnteroBiotix?
EnteroBiotix has 48 total employees.
-
What industry is EnteroBiotix in?
EnteroBiotix’s primary industry is Drug Discovery.
-
Is EnteroBiotix a private or public company?
EnteroBiotix is a Private company.
-
What is the current valuation of EnteroBiotix?
The current valuation of EnteroBiotix is .
-
What is EnteroBiotix’s current revenue?
The current revenue for EnteroBiotix is .
-
How much funding has EnteroBiotix raised over time?
EnteroBiotix has raised $105M.
-
Who are EnteroBiotix’s investors?
Kineticos Life Sciences, Home Furnishings Direct, Pioneer Group, The Scottish National Investment Bank, and Yike Zhengrun Investment Group are 5 of 20 investors who have invested in EnteroBiotix.
-
Who are EnteroBiotix’s competitors?
NovaBiotics, Quorum Innovations, Eligo Bioscience, Enterome, and 4D pharma are some of the 33 competitors of EnteroBiotix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
